Navigation Links
Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
Date:10/2/2007

Corrected Announcement Follows

NEW YORK, Oct. 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that I. Craig Henderson, MD, the Company's President, will present an overview of the Company's cancer pipeline at the upcoming William Blair & Company Small-Cap Growth Stock Conference in New York City. Dr. Henderson's presentation will take place on Wednesday, October 3rd at 12:00 noon ET.

Dr. Henderson's presentation will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX- 0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in- licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Onchocerciasis: Presentation And Treatment
2. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
3. New lease of life for asthmatics by Accentia Biopharmaceuticals
4. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
5. IDM Pharma Presents Preliminary Results of Melanoma Vaccine Clinical Trial
6. Living Liver Donor Who Saved Life of Mother-in-law Represents Cedars-Sinai in Rose Parade
7. Childrens Hospital Boston Presents at the Society for Adolescent Medicine Annual Meeting
8. Monogram Presents Results of First ETag Breast Cancer Studies
9. Novagali Pharma Presents Phase III Clinical Trial of Vekacia(R) for Vernal Keratoconjunctivitis
10. Recovering Pranab Mukherjee Likely to Be Discharged Tomorrow
11. Earth Day Celebrated With Hopes of a Greener Tomorrow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2020)... ... July 10, 2020 , ... 3Lions Publishing, Inc. (3LP), ... Partner Vetting (BPV) Portal . Expresso® 3.0 contains a Portal where potential and ... mailing, tracking, and performing other administrative tasks that amount to thousands of ...
(Date:7/4/2020)... ... July 03, 2020 , ... ... featured in Biocompare’s latest content hub— Future Lab: COVID-19 R&D . , ... advancements, trends, news, and products within specific scientific niches. Since their launch four ...
(Date:7/2/2020)... (PRWEB) , ... July 02, 2020 , ... ... its annual Outstanding Safety Professional of the Year Award to Eric Simmons of ... from more than 250 nominations. Simmons, who holds a master’s degree in occupational ...
(Date:7/1/2020)... ... July 01, 2020 , ... Psilera Bioscience ... psychedelics and analogues, announces its core executive team. The co-founders Drs. Jackie Salm ... novel formulations, and as distinguished researchers within the cannabis industry. They are joined ...
(Date:6/28/2020)... ... ... PathAI, a global provider of artificial intelligence (AI)-powered technology for use in ... PD-L1 expression to assess response in patients treated with Bristol Myers Squibb’s PD-1 inhibitor, ... Research (AACR) Annual Meeting. AACR was held June 22 to June 24. , The ...
Breaking Medicine News(10 mins):
(Date:6/25/2020)... , ... June 25, 2020 , ... ... by Innovate UK to build a distributed ledger platform to store COVID-19 related ... August, Billon will provide a fully functioning prototype for publishing, sharing and verifying ...
(Date:6/25/2020)... ... June 25, 2020 , ... The FSHD Society ... , which is being conducted entirely online for the first time in the ... the discussion and dissemination of state-of-the-art research on facioscapulohumeral muscular dystrophy (FSHD). A ...
(Date:6/24/2020)... ... June 24, 2020 , ... The Safe Boating Campaign, a worldwide effort ... under the influence, or BUI, is the leading contributing factor in recreational boater deaths, ... corner, and unfortunately has become known for drinking and boating, and deadly accidents,” said ...
Breaking Medicine Technology: